scispace - formally typeset
C

Carl Erik Mogensen

Researcher at Aarhus University

Publications -  146
Citations -  26633

Carl Erik Mogensen is an academic researcher from Aarhus University. The author has contributed to research in topics: Diabetes mellitus & Microalbuminuria. The author has an hindex of 63, co-authored 146 publications receiving 25685 citations. Previous affiliations of Carl Erik Mogensen include Herlev Hospital.

Papers
More filters
Journal ArticleDOI

Epidemiology of microalbuminuria in diabetes and in the background population.

TL;DR: New studies in insulin-dependent diabetes mellitus on the transition from normo- to microalbuminuria show that high normal excretion rate and poor metabolic control are associated with progression.
Journal ArticleDOI

Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study

TL;DR: Assessment for baseline proteinuria as a continuous covariate should be prespecified in the design and analysis of clinical trials involving renal outcomes, even when patients are stratified on the basis of level of proteinuria.
Journal ArticleDOI

Increased blood pressure in diabetes: essential hypertension or diabetic nephropathy?

TL;DR: It seems possible to distinguish diabetic patients with essential hypertension from diabetics with elevated blood pressure due to early or advanced nephropathy, and a positive correlation between UAE and blood pressure but a considerable overlap in BP and UAE values is found.
Journal ArticleDOI

Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy.

TL;DR: In a cohort of patients receiving antihypertensive treatment predominantly consisting of beta blockers in combination with diuretics, support for an improved survival has been presented and addition of ACE inhibition to such a combination treatment may be favorable both due to the suggested renoprotective effects of ACE inhibitors and because diuretic activate the renin-angiotensin system.
Journal ArticleDOI

Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria

TL;DR: The effect of simvastatin on OPG and adhesion molecules in type 2 diabetic patients at increased risk of CVD and potentially modifiable by statins is examined.